Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
By J. Vermorken, É. Remenár, C. V. van Herpen, T. Gorlia, R. Mesía, M. Degardin, J. Stewart, S. Jelić, J. Betka, J. Preiss and 8 more. New England Journal of Medicine, 2007
1,599 citations recorded by the source corpus.
Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/0f8f2c59b2e1fd18e4814f84ad3fbbffd59e82f3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Otorhinolaryngology
In Surgery
Citations in the corpus
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. (2009, neutral): “Since taxane-based induction chemotherapy also proved, in three recent randomised trials [16–18], to be superior to the reference 5-FU-platin-based induction chemotherapy, it is not possible to rule out that the benefit due to induction chemotherapy could be more pronounced that it appears to be in ”
- An update on larynx cancer (2017, methodology): “02) outcomes favored the TPF arm.(75) The TAX 324 study also randomized patients to receive induction PF versus TPF.”
- Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, neutral): “(92), which randomized 355 patients with”
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. (2011, result): “It should also be of note that trials using taxane, cisplatinum and 5-fluorouracil (TPF) as neoadjuvant chemotherapy are not included in this database so the results cannot be applied in this setting [15,16].”